JP2006527741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006527741A5 JP2006527741A5 JP2006516231A JP2006516231A JP2006527741A5 JP 2006527741 A5 JP2006527741 A5 JP 2006527741A5 JP 2006516231 A JP2006516231 A JP 2006516231A JP 2006516231 A JP2006516231 A JP 2006516231A JP 2006527741 A5 JP2006527741 A5 JP 2006527741A5
- Authority
- JP
- Japan
- Prior art keywords
- hfddde
- hexapeptide
- active ingredient
- preventing
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20030923A FI20030923A (fi) | 2003-06-19 | 2003-06-19 | Leukosyytti-proMMP-9/beta2-integriinikompleksin inhibiittorit |
| FI20040616A FI20040616A0 (fi) | 2004-04-29 | 2004-04-29 | Solumigraation inhibiittorit |
| PCT/FI2004/000376 WO2004110478A1 (fr) | 2003-06-19 | 2004-06-21 | Inhibiteurs de la migration cellulaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006527741A JP2006527741A (ja) | 2006-12-07 |
| JP2006527741A5 true JP2006527741A5 (fr) | 2007-08-02 |
Family
ID=33553915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516231A Withdrawn JP2006527741A (ja) | 2003-06-19 | 2004-06-21 | 細胞遊走の阻害剤 |
| JP2006516230A Withdrawn JP2006527740A (ja) | 2003-06-19 | 2004-06-21 | 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516230A Withdrawn JP2006527740A (ja) | 2003-06-19 | 2004-06-21 | 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤 |
Country Status (3)
| Country | Link |
|---|---|
| EP (2) | EP1644031A1 (fr) |
| JP (2) | JP2006527741A (fr) |
| WO (2) | WO2004110477A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1853624A2 (fr) * | 2005-01-31 | 2007-11-14 | Fondazione Centro San Raffaele Del Monte Tabor | Peptides therapeutiques derives de l'activateur du plasminogene de type urokinase |
| EP1924595A2 (fr) * | 2005-08-12 | 2008-05-28 | Cartela R & D AB | Nouveaux peptides et utilisations associees |
| GB2429012A (en) * | 2005-08-12 | 2007-02-14 | Cartela Ab | Polypeptides capable of binding an integrin I-domain. |
| EP2806028B1 (fr) * | 2008-11-04 | 2017-07-12 | InDex Pharmaceuticals AB | Composés et procédés de réduction du recrutement et/ou de la migration de cellules polymorphonucléaires |
| US8003110B1 (en) * | 2011-01-24 | 2011-08-23 | Matthias W. Rath | Metalloproteinase oligopeptides and their therapeutic use |
| JP2020514396A (ja) | 2017-03-22 | 2020-05-21 | ザ チルドレンズ メディカル センター コーポレーション | Ｌｒｐ１結合剤およびその使用 |
| WO2018175765A1 (fr) * | 2017-03-22 | 2018-09-27 | Children's Medical Center Corporation | Inhibition de prss2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817750A (en) * | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
| US20030022835A1 (en) * | 1998-04-29 | 2003-01-30 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
| GB9809764D0 (en) * | 1998-05-07 | 1998-07-08 | Isis Innovation | MMP-9 Gene polymorphisms |
| ES2327812T3 (es) * | 1999-07-13 | 2009-11-04 | University Of Southern California | Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1. |
| AU4347701A (en) * | 2000-03-01 | 2001-09-12 | Corixa Corp | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7034134B2 (en) * | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
| WO2003091391A2 (fr) * | 2002-04-23 | 2003-11-06 | Duke University | Genes determinants pour phenotype atheroscclerotique et methodes d'utilisation |
-
2004
- 2004-06-21 JP JP2006516231A patent/JP2006527741A/ja not_active Withdrawn
- 2004-06-21 EP EP04742118A patent/EP1644031A1/fr not_active Withdrawn
- 2004-06-21 JP JP2006516230A patent/JP2006527740A/ja not_active Withdrawn
- 2004-06-21 EP EP04742119A patent/EP1644032A1/fr not_active Withdrawn
- 2004-06-21 WO PCT/FI2004/000375 patent/WO2004110477A1/fr not_active Application Discontinuation
- 2004-06-21 WO PCT/FI2004/000376 patent/WO2004110478A1/fr not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2017047I1 (no) | Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt | |
| DK1183014T3 (da) | Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse | |
| JP2004210767A5 (fr) | ||
| WO2008011169A3 (fr) | Formulations à libération contrôlée et procédés associés | |
| JP2007523135A5 (fr) | ||
| WO2006035418A3 (fr) | Produits de combinaison | |
| DE50313653D1 (de) | Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel | |
| TNSN07304A1 (en) | Combination of xolair with immunosuppressive agent | |
| WO2004056337A3 (fr) | Formes posologiques orales comprenant des agents actifs au plan therapeutique dans des noyaux a liberation lente et des revetements de capsule en gelatine a liberation immediate | |
| EP1995246A4 (fr) | Derive heterocyclique azote et agent pharmaceutique comprenant le derive en tant que principe actif | |
| JP2002511411A5 (fr) | ||
| JP2005518413A5 (fr) | ||
| UA88477C2 (ru) | Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение | |
| EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
| CL2007003444A1 (es) | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. | |
| JP2008515980A5 (fr) | ||
| WO2006121964A3 (fr) | Compositions sous forme de suspensions de nepafenac et d'autres medicaments ophtalmiques pour le traitement topique de troubles ophtalmiques | |
| IS8430A (is) | Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn | |
| EP1731609A4 (fr) | INHIBITEUR DE L'EXPRESSION DE Rad51, MÉDICAMENT CONTENANT L'INHIBITEUR COMME INGRÉDIENT ACTIF ET UTILISATION DE CELUI-CI | |
| ITMI20022292A1 (it) | 9a-azalidi ad attivita' antiinfiammatoria. | |
| DE60102590D1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| JP2005509503A5 (fr) | ||
| IL187575A (en) | Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders | |
| JP2006527741A5 (fr) | ||
| EA200702386A1 (ru) | Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения |